Business Context and Reporting Period
This Form 8-K filing by Bone Biologics Corp (BBLG) covers events occurring on December 12, 2023. The report details the results of a special meeting of stockholders and updates regarding the company's listing status on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and regulatory compliance rather than financial performance.
Material Changes and Voting Results
On December 12, 2023, the company held a special meeting where 1,580,982 shares were present or represented by proxy out of 3,134,391 entitled to vote. Stockholders approved two key proposals:
- Proposal One: Approval of an amendment to the Certificate of Incorporation to effect a reverse stock split of Common Stock in a range of 1-for-5 to 1-for-20, at the board's discretion.
- For: 1,402,685 shares
- Against: 162,168 shares
- Abstain: 16,129 shares
- Proposal Two: Approval to adjourn the meeting if necessary to solicit additional votes or establish a quorum.
- For: 1,394,105 shares
- Against: 170,748 shares
- Abstain: 16,129 shares
Outlook, Risks, and Regulatory Status
Nasdaq Compliance: The company previously received a delisting notice on September 27, 2023, for failing to meet the $1.00 minimum bid price requirement. On December 11, 2023, the Nasdaq Hearings Panel granted continued listing until January 12, 2024, contingent on the company meeting milestones related to the reverse stock split and demonstrating compliance with the minimum bid price.
Risks and Forward-Looking Statements: Management explicitly states there is no assurance that the company will successfully implement its plan or meet the Nasdaq milestones. Failure to do so could result in delisting. The filing includes standard disclaimers that actual results may differ materially from forward-looking statements.
Investor Verification Checklist
- Verify the specific reverse stock split ratio (1-for-5 to 1-for-20) selected by the Board of Directors.
- Monitor the company's stock price to ensure it meets the $1.00 minimum bid price requirement before the January 12, 2024 deadline.
- Confirm the effective date of the reverse stock split and the impact on share count and liquidity.
- Review subsequent filings for updates on the Nasdaq compliance milestones.